U.K.-based breast imaging company Micrima has received 3.1 million euros (2.6 million pounds) in financing to further develop its radiowave breast screening technology.
The technology, called MARIA, uses radio waves to identify tumors in dense tissue, allowing for routine and repeated scanning without any of the safety or comfort concerns associated with x-ray mammography, according to the firm.
Half of the new funds come from current investors, which include Technology Venture Partners, Swarraton Partners, and Angel CoFund; the University of Bristol Enterprise Fund is a new investor, Micrima said.
The company's MARIA breast imaging technology received European regulatory approval in 2015 and is currently being used in clinical trials at several breast cancer imaging centers throughout the U.K., Micrima said.
